RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and pan-viral respiratory therapies Company also...

RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital FARMINGTON, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- RIGImmune Inc., a biopharmaceutical company developing a new class of RNA immunotherapeutics, today announced the acquisition of Subintro, a...